21 May 2025 in Advanced Science
Atherosclerosis, a chronic inflammatory disorder and leading cause of cardiovascular disease, is characterized by macrophage‐derived inflammation and foam cell formation. Emerging evidence suggests that metabolic reprogramming of macrophages represents a promising therapeutic approach for atherosclerosis management. In this study, the therapeutic potential of wogonin, a bioactive flavonoid isolated from Scutellaria baicalensis, in modulating macrophage metabolism and attenuating atherogenesis is investigated. Wogonin reduces lesion size and plaque vulnerability, accompanied by a reduction in foam cell formation and inflammation. Mechanistically, wogonin reprogrammes macrophage metabolism from glycolysis to fatty acid oxidation (FAO) by activating the PPARα‐CPT1α pathway and acts as a mitochondrial protector by activating PPARα. Wogonin also promotes the KLF11 expression and KLF11 knockout exacerbated atherosclerosis and abolishes the inhibitory effect of wogonin on glycolysis and atherosclerosis. KLF11 forms a transcriptional complex with PPARα and YAP1, serving both as a brake on PPARα‐YAP1‐mediated glycolysis and a transcriptional activator of ABCA1/G1. Collectively, wogonin reprograms macrophage metabolism from glycolysis to FAO through activation of the PPARα‐KLF11‐YAP1 pathway, thereby reducing inflammation and foam cell formation, ultimately attenuating atherogenesis.
25 November 2021 in Frontiers in Pharmacology
Background and purpose: FXR is a promising target for the treatment of human cholestatic liver disease (CLD). SIRT1 is a deacetylase which promotes FXR activity through deacetylating FXR. Pterostilbene (PTE) is an activator of SIRT1. However, the role of PTE in cholestasis has so far not been investigated. We examined whether PTE treatment alleviate liver injury in DDC or ANIT-induced experimental cholestasis, and explored the underlying mechanisms.Experimental approach: Mice with DDC- or ANIT-induced cholestasis were treated with different dose of PTE. Primary hepatocytes and bone marrow derived macrophages were used in vitro to assess the molecular mechanism by which PTE may improve CLD. Identical doses of UDCA or PTE were administered to DDC- or ANIT-induced cholestasis mice.Key results: PTE intervention attenuated DDC or ANIT-induced cholestasis. PTE inhibited macrophage infiltration and activation in mouse liver through the SIRT1-p53 signaling pathway, and it improved hepatic bile metabolism through the SIRT1-FXR signaling pathway. Compare with UDCA, the same doses of PTE was more effective in improving cholestatic liver injury caused by DDC or ANIT.Conclusion and implications: SIRT1 activation in macrophages may be an effective CLD treatment avenue. Using CLD models, we thus identified PTE as a novel clinical candidate compound for the treatment of CLD.
19 May 2026 in Frontiers in Bioscience-Landmark
Cardiovascular diseases (CVDs) are the primary cause of mortality globally. The Global Burden of Disease Study indicates that CVDs account for one-third of all global deaths, with a notable 18.17% increase in their incidence over the last decade. Despite the widespread use and proven effectiveness of therapies like antiplatelet agents, lipid-lowering drugs, anticoagulants, and percutaneous coronary intervention (PCI) in managing risk factors, the long-term prognosis of patients remains suboptimal. The prevailing academic viewpoint asserts that chronic inflammation and dysregulated apoptosis lead to the accumulation of apoptotic cells or fragments, triggering inflammatory injury and oxidative stress. Efferocytosis, encompassing the recognition, engulfment, and degradation of apoptotic cells by phagocytes, is essential for preserving tissue homeostasis and limiting excessive inflammation in this context. Macrophages, being professional phagocytes, demonstrate the highest efficiency and precision in clearing apoptotic cells. Hence, this review will center on macrophage-mediated efferocytosis, systematically investigating its roles and mechanisms in the pathogenesis and progression of CVDs.